
Generalized Anxiety Disorder - Pipeline Insight, 2024
Description
Generalized Anxiety Disorder - Pipeline Insight, 2024
DelveInsight’s, “Generalized Anxiety Disorder (GAD) – Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Generalized Anxiety Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Generalized Anxiety Disorder (GAD): Overview
Generalized Anxiety Disorder (GAD) is characterized by persistent and excessive worry about a number of different things. People with Generalized Anxiety Disorder may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with Generalized Anxiety Disorder find it difficult to control their worry. They may worry more than seems warranted about actual events or may expect the worst even when there is no apparent reason for concern. People with generalized anxiety disorder (GAD) display excessive anxiety or worry, most days for at least 6 months, about a number of things such as personal health, work, social interactions, and everyday routine life circumstances. The fear and anxiety can cause significant problems in areas of their life, such as social interactions, school, and work.
Symptoms
- Generalized anxiety disorder symptoms include:
- Feeling restless, wound-up, or on-edge
- Being easily fatigued
- Having difficulty concentrating; mind going blank
- Being irritable
- Having muscle tension
- Difficulty controlling feelings of worry
- Having sleep problems, such as difficulty falling or staying asleep, restlessness, or unsatisfying sleep
“Generalized Anxiety Disorder - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Generalized Anxiety Disorder pipeline landscape is provided which includes the disease overview and Generalized Anxiety Disorder treatment guidelines. The assessment part of the report embraces, in depth Generalized Anxiety Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Generalized Anxiety Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Generalized Anxiety Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Generalized Anxiety Disorder.
This segment of the Generalized Anxiety Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Generalized Anxiety Disorder Emerging Drugs
- MM-120: Mind Medicine, Inc.
- ENX-102: Engrail therapeutics
Further product details are provided in the report……..
Generalized Anxiety Disorder: Therapeutic Assessment
This segment of the report provides insights about the different Generalized Anxiety Disorder drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Generalized Anxiety Disorder
Phases
DelveInsight’s report covers around 12+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Peptides
- Product Type
Generalized Anxiety Disorder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Generalized Anxiety Disorder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Generalized Anxiety Disorder drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Generalized Anxiety Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Generalized Anxiety Disorder.
- Generalized Anxiety Disorder Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Generalized Anxiety Disorder drugs?
- How many Generalized Anxiety Disorder drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Generalized Anxiety Disorder?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Generalized Anxiety Disorder therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Generalized Anxiety Disorder and their status?
- What are the key designations that have been granted to the emerging drugs?
- Tilray
- Mind Medicine, Inc.
- PSY Therapeutics
- Pear Therapeutics
- Engrail Therapeutics
- Bionomics
- Sage Therapeutics
- Seed Health
- OWP Pharmaceuticals
- Cannabidiol
- MM-120
- PSY-05
- Pear-011
- ENX-102
- BNC210
- Zuranolone
- Duloxetine Hydrochloride
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Generalized Anxiety Disorder : Overview
- Introduction
- Pathogenesis
- Risk factors
- Diagnosis
- Signs and Symptoms
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Assessment by Product Type
- Assessment by Stage and Product Type
- Generalized Anxiety Disorder – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- MM-120: Mind Medicine, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- PSY-05: PSY Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Discovery Stage Products
- Comparative Analysis
- Pear-011: Pear Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Generalized Anxiety Disorder - Collaborations Assessment- Licensing / Partnering / Funding
- Generalized Anxiety Disorder - Unmet Needs
- Generalized Anxiety Disorder - Market Drivers and Barriers
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.